StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 8.7
Power Rank trend -> Rising
03/27/2025 16:00:00 EST
Biomarin Pharmaceutical Inc (BMRN)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, BMRN has been trading in a range between $72.23 and $69.12 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
BMRN is trading below resistance at $93.84, about 29% to the upside. There is support at $71.16 -2% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Biomarin Pharmaceutical Inc $BMRN entered a Green zone 38 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $97.6627, a potential upside of 36.63% from the recent price of 71.48. The stock is trading 32.69% (potential upside) below its 52 week high of $94.85 and 17.9 % (potential downside) above its 52 week low of $60.63 - based on the recent price.
Company Summary
BioMarin Pharmaceutical Inc, a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
News
| 5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction Every so often, Wall Street sends a not-so-subtle reminder to investors that stocks can move in both directions. Source: The Motley Fool Thu, 27 Mar 2025 05:06:00 -0400 Sentiment: Positive |
| BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? Source: Zacks Investment Research Fri, 21 Mar 2025 12:36:49 -0400 Sentiment: Positive |
| Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Source: Zacks Investment Research Fri, 21 Mar 2025 11:10:25 -0400 Sentiment: Positive |
| BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif. , March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO ® (vosoritide) in children with achondroplasia and in ongoing clinical trials investigating other skeletal conditions, as well as PALYNZIQ ® (pegvaliase-pqpz) in adults with phenylketonuria (PKU). Source: PRNewsWire Thu, 20 Mar 2025 09:00:00 -0400 Sentiment: Neutral |
| BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors? Source: Zacks Investment Research Tue, 18 Mar 2025 12:40:20 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 94.85 52 Week Low: 60.63 Beta: 0.329 50 Day MA: 67.1914 200 Day MA: 73.5448 Earnings / Revenue Trends Qtr Earnings Growth YOY: 6.449 Qtr Revenue Growth YOY: 0.156 Forward PE: 18.2149 Trailing PE: 32.3689